HSE statement confirms the NCPE is being asked to undertake a 'priority assessment.'

Following recent engagements, the HSE expects that Vertex will be submitting a Heath Technology Appraisal (HTA) dossier to the National Centre for Pharmacoeconomics (NCPE) covering Kaftrio® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor for the cohort of children aged 6-11 years of age who are not currently receiving reimbursed access.

The HSE has asked the NCPE to undertake a priority assessment once the dossier is submitted, with a view to bringing the case in front of HSE decision makers as soon as possible.